1. The Future of B-Cell Therapies in MS and NMOSD
  2. Targeting the Innate Immune System in PMS
  3. Development and Use of Biomarkers
  4. MRI Measures of Atrophy in the Clinic


OPEN FORUM (with Lunch)*

Thursday, 1 November 2018
Grand Ballroom, Level B
11:30-12:30 Open Forum (with Lunch):
General Principles for the Treatment of MS and NMOSD in the PACTRIMS Region
Moderator: Ernest Willoughby (New Zealand) & William Carroll (Australia)

*Delegates must indicate their attendance to the Secretariat at



Thursday, 1 November 2018
Grand Ballroom, Level B
13:00-14:30 European Charcot Foundation Symposium
Are Disease Phenotypes Still Valuable in the Treatment of MS?
Chairperson: Giancarlo Comi (Italy) & William Carroll (Australia)
1. Does the Pathology of Early and Late MS Reflect Disease Phenotypes?
– Michael Barnett (Australia)
2. Is the Value of Clinical Trials Diminishing?
– Hans-Peter Hartung (Germany)
3. Contribution of Post Marketing Studies
– Tomas Kalincik (Australia)
4. Should We Change Our Treatment Strategies?
– Giancarlo Comi (Italy)
14:30-15:00 Coffee Break
15:00-15:15 Opening Ceremony
1. Welcome Address by the Chairman, 2018 Local Organising Committee
– Michael Barnett (Australia)
2. Opening Address by the President, PACTRIMS
– Takahiko Saida (Japan)
3. Special Remarks by the Minister for Health (Australia)
– Hon Greg Hunt MP (Australia)
15:15-17:10 Opening Lecture Series
Opening Lecture-1
Chairperson: William Carroll (Australia)
L-1 Environmental Control of Astrocyte Pathogenic Activities in CNS Inflammation
– Francisco Javier Quintana (USA)
Opening Lecture-2
Chairperson: Michael Barnett (Australia)
L-2 Environmental Risk Factors and Alteration of Innate Gamma Delta T Cells in Asian Multiple Sclerosis
– Noriko Isobe (Japan)
Opening Lecture-3
Chairperson: Masoud Etemadifar (Iran)
L-3 Multiple Sclerosis in the MENA Region
– Bassem Yamout (Lebanon)
17:10-17:30 Coffee Break & Poster Viewing
17:30-19:00 Merck Sponsored Symposium
Regenerating Immune Tolerance in Multiple Sclerosis – Understanding Immune Reconstitution as a Therapeutic Approach
19:30-21:00 Welcome Reception @ Heritage, Level G, Shangri-La Hotel, Sydney


Friday, 2 November 2018
Grand Ballroom, Level B
08:00-09:30 Sanofi Genzyme Sponsored Symposium
From Bench to Bedside – New Treatment Concepts to Make a Difference for Multiple Sclerosis Patients
09:30-09:45 Coffee Break
09:45-10:50 Plenary Oral Presentation-1
NMOSD and MOG Antibody Disease
Chairperson: Todd Hardy (Australia)
O-1 Withdrawn
O-2 Clinical features of myelin oligodendrocyte glycoprotein-antibody+ disease: a study of 369 Japanese cases.
– Kimihiko Kaneko (Japan)
O-3 Withdrawn
O-4 Perivenous Inflammatory Demyelination with Myelin Oligodendrocyte Glycoprotein (MOG)-dominant Myelin Loss and CD4-dominant T cell Infiltration is Prominent in MOG Antibody-associated Disease
– Yoshiki Takai (Japan)
O-5 Quantitative Susceptibility Mapping in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
– Woojun Kim (Republic of Korea)
10:50-11:55 Plenary Oral Presentation-2
Multiple Sclerosis
Chairperson: Joyce Joseph (Malaysia)
O-6 Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as potential biomarkers for disease activity and disability in neuromyelitis optica spectrum disorders and multiple sclerosis
– Mitsuru Watanabe (Japan)
O-7 Filling in the Gaps: Precision Magnetic Resonance Imaging Reporting in Multiple Sclerosis Clinical Practice
– Heidi Beadnall (Australia)
O-8 Decreased Rice Intake is a Unique Risk Factor for Multiple Sclerosis in Japanese People in Addition to Smoking, Earlier Menarche, and Low Sunlight Exposure in Childhood
– Sakoda Ayako (Japan)
O-9 Genome-wide DNA Methylation in Secondary Progressive Multiple Sclerosis Patients Reveals Unique Epigenetic Signature
– Vicki Maltby (Australia)
O-10 HLA-DRB1*15:01 Protects and DR4 Facilitates JCV Infection in Japanese Patients with Multiple Sclerosis
– Yuri Nakamura (Japan)
11:55-12:20 Two Minute Oral Presentation of Selected Posters
Chairperson: Naraporn Prayoonwiwat (Thailand)
O-11 Memantine and pioglitazone ameliorate motor impairments and complement-independent cord pathologies in mice received aquaporin-4 autoantibodies from neuromyelitis optica spectrum disorder (NMOSD) patients.
– Koon-Ho Chan (Hong Kong)
O-12 Astrocytic interleukin-15 reduces pathology of neuromyelitis optica in mice
– Zhiguo Li (China)
O-13 Relapse After Cessation Or Un-treatment Of Immunosuppressants In Neuromyelitis Optica Spectrum Disorder With Long-term Remission
– SG Ryu (Republic of Korea)
O-14 Quantitative evaluation of cervical spine damage in MS patients and its correlation with EDSS by using diffusion tensor MR imaging
– A. Eftekhari (Iran)
O-15 Brain Atrophy is Associated with Higher Serum Amyloid A Levels in Patients with Relapsing and Remitting Multiple Sclerosis and Clinically Isolated Syndrome
– Hiroaki Yokote (Japan)
O-16 Brain volume loss can predict cognitive impairments by neuropsychological battery in a cross-sectional study of Chinese patients with multiple sclerosis
– Angel Ng (Hong Kong)
O-17 q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with glatiramer acetate
– Kenji Kufukihara (Japan)
O-18 Increased plasma-borne extracellular vesicles in Multiple Sclerosis – Where did they come from?
– Kira Groen (Australia)
O-19 Functional Immune-phenotyping in Fingolimod-treated Multiple Sclerosis Patients: Assessing Drug Effects and Treatment Response Biomarkers
– Mahtab Ghadiri (Canada/Australia)
12:20-13:20 Lunch @ Café Mix, Level 1 & Bradfield Lounge, Level 1, & Poster Viewing
13:20-14:50 Symposium-1
Monitoring of Demyelinating Disease Activity, Treatment Response, and Outcomes
Chairperson: Kazuo Fujihara (Japan) & Ernest Willoughby (New Zealand)
L-4 MRI Brain Atrophy Assessment in Multiple Sclerosis Clinical Practice
– Heidi Beadnall (Australia)
L-5 Passive and Active Monitoring Applications and Devices
– Helmut Butzkueven (Australia)
L-6 Artificial Intelligence in the Monitoring and Management of MS
– Fu-Dong Shi (China)
14:50-15:20 Coffee Break & Poster Review
15:20-17:20 Symposium-2
Biomarkers for Inflammatory CNS Demyelinating Disease Based on the Disease Mechanism
Chairperson: Jun-ichi Kira (Japan) & Helmut Butzkueven (Australia)
L-7 Serum Biomarkers for MS Related to Inflammatory and Degenerating Processes
– David Leppert (Switzerland)
L-8 CSF Biomarkers for NMOSD
– Shuhei Nishiyama (Japan)
L-9 MRI Markers that Differentiate NMOSD from MS
– Yaou Liu (China)
L-10 OCT and Eye Movement Markers to Monitor MS Disease Activity
– Owen White (Australia)
17:20-17:30 Coffee Break
17:30-19:00 Biogen Sponsored Symposium
Moving Towards Personalisation of Therapy
19:30-23:30 Presidential Dinner @ O Bar and Dining


Friday, 2 November 2018
Heritage Room, Level G (Breakout Session)
15:20-17:20 Symposium-3
Comprehensive Management of MS and NMOSD in Asia-Pacific Regions
Chairperson: Alvin Seah (Singapore) & Jen-Jen Su (Taiwan)
L-11 Practical Issues in the Management of Relapsing Inflammatory CNS Diseases in the Asia-Pacific Region
– Shanthi Viswanathan (Malaysia)
L-12 Aggressive MS: How to Define and How to Manage It
– Ho Jin Kim (Republic of Korea)
L-13 The Approach to the Management of Indeterminate MS/NMOSD
– Kazuo Fujihara (Japan)
L-14 Symptomatic Management of MS: What Works and What Doesn’t
– Simon Broadley (Australia)


Saturday, 3 November 2018
Grand Ballroom, Level B
08:00-09:30 Roche Sponsored Symposium
Ocrelizumab: Continued Experience Targeting B Cells in MS
09:30-10:00 Coffee Break & Poster Review
10:00-12:10 Symposium-4
Immune Mechanisms and Next Generation Monoclonal Antibody Therapies in MS and Allied Disorders
Chairperson: Allan Kermode (Australia) & Makoto Matsui (Japan)
L-15 Keynote Lecture: Landscape of B Cell Therapies and Possible Mechanisms of Action in MS
– Heinz Wiendl (Germany)
L-16 Anti-IL6 Receptor Monoclonal Antibody Therapy in NMOSD
– Manabu Araki (Japan)
L-17 Anti-C-C chemokine receptor 4 monoclonal antibody therapy in human T-lymphotropic virus type 1-associated myelopathy (HAM/TSP)
– Yoshihisa Yamano (Japan)
12:10-12:20 Closing and Award Ceremony
1. Award Ceremony
– Jun-ichi Kira (Japan)
2. Closing Remarks by the Vice President, PACTRIMS
William Carroll (Australia)


*subject to change